Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
For diabetes mellitus. Sold as Lyumjev. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Insulin Lispro-Aabc (sold as Lyumjev), first approved Jun 15, 2020, with 2 new uses approved and 0 published complete response letters.
First approved: Jun 15, 2020
Applications: 1
New uses approved: 2
Complete response letters: 0
Medicare spending, 2025: $106M
First approved in the EU: Apr 30, 1996
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Humalog Cart Humalog MiriopenDrugs with a new dosage indicated for the treatment of diabetes mellitus in cases where insulin therapy is indicated. · Eli Lilly Japan K.K. · Dec 19, 2016
Humalog MixDrugs with a new dosage indicated for the treatment of diabetes mellitus where insulin therapy is indicated. · Eli Lilly Japan K.K. · Aug 20, 2009
Applications
NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history
Approved
Application
Sponsor
Supplements
Marketing
Jun 15, 2020
LyumjevBLA 761109 · New formulation or manufacturer
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
